Hong Kong · Delayed Price · Currency is HKD Alphamab Oncology Company Description
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China.
It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand.
Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.
In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors.
The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 498 |
| CEO | Ting Xu |
Contact Details
Address: No. 175 Fangzhou Road Suzhou, 215127 China | |
| Phone | 86 512 6285 0800 |
| Website | alphamabonc.com |
Stock Details
| Ticker Symbol | 9966 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG0330A1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ting Xu Ph.D. | Founder, Executive Chairman and Chief Executive Officer |
| Yang Liu | Chief Operating Officer and Executive Director |
| Fei Wang CPA | Chief Financial Officer |
| Dr. Hongwei Wang | Chief Technology Officer |
| Yumin Wan | Vice President of Government Affairs and Public Relations |
| Dr. Mike Liu M.B.A., Ph.D. | Senior Vice President of Business Development |
| Jing Han | Chief Commercial Officer |
| Lok Yee Chan A.C.I.S., A.C.S. | Joint Company Secretary |
| Rui Jiang | Joint Company Secretary |